Struggling with the challenges of Premature Ovarian Failure? We have a natural, effective, and non-invasive solution.

Recent advances in Regenerative Medicine have identified expanded Mesenchymal
Stem Cells (MSCs) as a promising treatment to restore ovarian function in women
with POF.

Expanded Mesenchymal Stem Cells (MSCs) represent a paradigm shift in Reproductive Medicine: From managing decline to restoring function.

For women seeking a natural, effective, and non-invasive solution to Premature Ovarian Failure, this is the Gold Standard treatment option - superior to anything currently available on the market. Expanded Mesenchymal Stem Cells (MSCs) are now emerging as the most advanced and effective treatment, with the unique ability to restore ovarian health from within.

What is Premature Ovarian Failure (POF)?

Premature Ovarian Failure (POF) - also known as Primary Ovarian Insufficiency (POI) - is a condition in which the ovaries stop functioning normally before the age of 40. Unlike natural menopause, which typically occurs between ages 45 and 55, POF results in the early loss of fertility, irregular or absent menstrual cycles, and a significant decline in estrogen levels at a young age.

Symptoms:

  • Irregular or missed periods (amenorrhea)

  • Hot flashes and night sweats

  • Vaginal dryness and low libido

  • Mood swings, depression, or anxiety

  • Difficulty conceiving (infertility)

  • Fatigue and difficulty concentrating

  • Decreased bone density

Main Causes:

  • Genetic abnormalities (such as Turner Syndrome or Fragile X premutation)

  • Autoimmune disorders

  • Chemotherapy or radiation therapy for cancer

  • Environmental toxins and lifestyle factors

  • Infectious diseases (such as mumps oophoritis)

  • Idiopathic (unknown origin), in many cases

Physical
Consequences

Osteoporosis and increased risk of bone fractures
Cardiovascular disease due to low estrogen levels
Accelerated aging of skin and tissues
Weight gain and metabolic changes

Psychological and Emotional
Consequences

Loss of identity or femininity

Anxiety and depression

Emotional distress from infertility

Strained relationships and decreased quality of life

Physiological Basis

Premature Ovarian Failure occurs when the ovaries lose their normal function before the age of 40. In healthy ovaries, a complex interaction between follicular cells, granulosa cells, and hormonal signaling (primarily FSH and LH) supports folliculogenesis, estrogen production, and ovulation. In POF, this physiological balance is disrupted due to:

  • Depletion or dysfunction of ovarian follicles

  • Increased apoptosis of granulosa cells

  • Reduced vascularization and oxygenation of ovarian tissue

  • Chronic inflammation or autoimmune reactions

  • Oxidative stress and mitochondrial dysfunction

These alterations lead to hypoestrogenism, irregular ovulation, and often irreversible infertility. In many cases, the ovarian reserve is not completely depleted, but the microenvironment is too damaged to support proper follicular maturation.

Conventional Treatments and their Limitations:

Today, most women diagnosed with Premature Ovarian Failure are offered symptomatic treatments rather than true solutions aimed at restoring ovarian function. Common options include:

Hormone Replacement Therapy (HRT)

Helps manage symptoms such as hot flashes, vaginal dryness, and bone loss by replacing estrogen and progesterone. However, it does not restore fertility or ovarian activity.

Egg Donation and IVF

Allows pregnancy but requires the use of a donor’s eggs, and does not recover natural ovulation or hormonal balance.

Nutritional and lifestyle changes

Can support overall health but do not regenerate ovarian tissue.

These alterations lead to hypoestrogenism, irregular ovulation, and often irreversible infertility. In many cases, the ovarian reserve is not completely depleted, but the microenvironment is too damaged to support proper follicular maturation.

Can’t wait to feel like yourself again?

How?

It’s easier than you think. Discover the world’s most advanced Stem Cell and Exosomes treatment. Reach out to us — we’re here for you and happy to answer any questions you may have.

Where?

Help Desk +390549909905
Help Desk info@bioinst.com

Como (Italy)
Milano (Italy)
Rome (Italy)
Varese (Italy)
Falciano (RSM)

The Stem Cells Treatment: Minimally Invasive Procedure

For patients suffering from Peyronie’s disease the combined mesenchymal stem cell and collagenase treatment represents a state-of-the-art solution. Here’s why this therapy is considered by many experts as a “gold standard”approach moving forward:

  • Regenerating damaged ovarian tissue

  • Stimulating angiogenesis (formation of new blood vessels)

  • Modulating the immune response, reducing chronic inflammation

  • Secreting growth factors and cytokines that enhance follicular survival and
    activation

  • Inhibiting apoptosis of granulosa and stromal cells

  • Improving mitochondrial function and reducing oxidative damage

At the forefront of innovative treatment, expanded MSCs are delivered directly into the ovaries through a minimally invasive intravaginal injection, guided by ultrasound for precision and safety. This technique ensures that the regenerative cells reach the ovarian stroma, where they can interact directly with dormant or damaged follicles to promote local repair and reactivate natural hormone production and ovulation in some cases.
Stem Cell Procedure

Let’s clarify with accurate information:

Stem Cells obtained from a fat sample require at least two weeks of processing before they can be used; otherwise, the treatment is ineffective and potentially harmful:

  • Fat that is harvested and manipulated for use in the same session is both useless and harmful.
  • There are no Stem Cells in the blood, so treatments claiming to use stem cells extracted from blood are not scientifically valid. The Stem Cells used to treat hematological diseases are found in the bone marrow, not in the blood.
  • The hematopoietic stem cells found in umbilical cord blood are useful for treating blood disorders, but not for counteracting the aging processes of the human body

Stem Cells is the Gold Standard

Expanded MSCs represent a paradigm shift in reproductive medicine: from managing decline to restoring function. For women seeking a natural, effective, and non-invasive solution to Premature Ovarian Failure, this is the Gold Standard treatment option - superior to anything currently available on the market. Expanded Mesenchymal Stem Cells (MSCs) are now emerging as the most advanced and effective treatment for Premature Ovarian Failure, with the unique ability to restore ovarian health from within. why is superior:

Regenerative, Not Just Symptomatic

MSCs work by repairing and regenerating ovarian tissue, restoring the natural production of estrogen and potentially reactivating folliculogenesis and ovulation.

Safe and Biocompatible

MSCs are typically autologous (from the patient’s own tissue) or allogenic but immunologically safe, with no risk of rejection or tumor formation.

Targeted Delivery

Through ultrasound-guided intravaginal injection, the cells are delivered precisely into the ovaries - no general anesthesia or surgery required.

Multifactorial Mechanism of Action

MSCs secrete a wide range of anti-inflammatory, pro-angiogenic, and anti-apoptotic factors that restore a healthy ovarian microenvironment - something no drug or hormone can replicate.

Potential to Restore Fertility

Unlike conventional methods, stem cell therapy offers the real possibility of resuming natural menstrual cycles, ovulation, and even spontaneous pregnancy.

Long-Term Impact

While HRT and IVF are temporary and repetitive, MSC therapy offers a long-lasting regenerative effect, targeting the root cause of POF.

Contact us Today

Why?

Because you deserve to feel great again. To feel like yourself. The solution exists — it’s real, and it starts with your choice.

Where?

Help Desk +390549909905
Help Desk info@bioinst.com

Como (Italy)
Milano (Italy)
Rome (Italy)
Varese (Italy)
Falciano (RSM)

Expected Timeline Of Results

Clinical and preclinical studies show:

  • Menstrual cycle restoration may occur within 2 to 6 months post-treatment
  • Hormone improvements—lowered FSH and raised estrogen and AMH levels—are typically seen within 1 to 3 months, sustained thereafter
  • Follicular development and ovulation: increased antral, dominant, and mature follicles have been observed after 3–4 months
  • Pregnancies in treated women (case reports) occurred between 6 and 12 months, although evidence is still limited to small cohorts

Number of Treatments Needed:

  • The majority of studies report a single injection may be sufficient to trigger ovarian activity and hormonal improvement.
  • In cases where response is limited, a second injection after 3–6 months may be considered, guided by hormone levels and ultrasound findings
  • Long-term follow-up studies are

Step by Step

  • Step 1: Patient Evaluation and Diagnosis
    Before treatment begins, a comprehensive evaluation is performed to:
    - Confirm diagnosis of Premature Ovarian Failure
    - Assess ovarian reserve (via AMH levels, FSH, LH, and ultrasound)
    - Review medical history and eligibility for MSC therapy

  • Step 2: Stem Cell Preparation
    - Mesenchymal stem cells are obtained from a biocompatible source (usually the patient’s own tissue or umbilical cord-derived allogenic MSCs)
    - Cells are isolated, purified, and expanded under Bioscience Institute GMP-certified laboratory - conditions to achieve optimal therapeutic concentration

  • Step 3: Scheduling the Procedure
    - The treatment is performed in an outpatient setting
    - No general anesthesia or hospitalization is required
    - The procedure takes approximately 20–30 minutes

  • Step 4: Intravaginal Ovarian Injection
    - The MSCs are injected directly into the ovaries using a transvaginal ultrasound-guided needle
    - This approach ensures precise, targeted delivery to the ovarian cortex, where dormant follicles and stromal tissue can benefit from the regenerative effect
    - The procedure is non-invasive, painless, and performed without incisions

  • Step 5: Recovery and Follow-Up
    - Patients can resume normal activity within 24 hours
    - Follow-up visits include hormonal profiling and ultrasound scans to monitor signs of ovarian reactivation
    - In some cases, menstrual cycles may resume within a few weeks to months

The Unique Procedure:

  • No surgery, no scars, no general anesthesia
  • High-precision targeting of ovarian tissue
  • Real potential to restore natural hormone production and fertility
  • Zero downtime and minimal discomfort

The Stem Cell Source

Mesenchymal stem cells are the same regardless of whether they are derived from Adipose Tissue or Umbilical Cord Tissue. The only difference lies in their biological age, which reflects the age of the tissue of origin.

Adipose Tissue Derived Stem Cells 

The treatment requires a fat collection, stem cell extraction, and expansion. The entire process takes approximately 2–3 weeks. Therefore, from the moment of fat harvesting, a waiting period of 2–3 weeks is necessary before the treatment can be performed.

Umbilical Cord Tissue derived Stem Cells

The treatment does not require fat harvesting and can be performed within 2–3 days of the request.

Why Patient Selection Matters

Expanded MSC therapy is most effective when there is still some functional ovarian tissue present. Women with partial follicular function or residual vascularity tend to respond better than those with complete ovarian failure or fibrosis. Personalized assessment increases the chances of menstrual cycle recovery, hormonal improvement, and potential fertility restoration.

Who Is Eligible?

Not all women with Premature Ovarian Failure (POF), also known as Primary Ovarian Insufficiency (POI), are automatically eligible for regenerative treatment using expanded Mesenchymal Stem Cells (MSCs). Proper patient selection is critical to maximize success rates and ensure safety. Here are the general eligibility requirements:

Inclusion Criteria

You may be considered a good candidate for MSC therapy if you meet most of the following conditions:

  • Age between 18 and 42 years
    • Women under 43 tend to respond better due to higher residual ovarian
      responsiveness.
  • Diagnosed with Premature Ovarian Failure or Primary Ovarian Insufficiency - Characterized by:
    • Elevated FSH levels (>25 mIU/mL on two tests at least 4 weeks apart)
    • Low or undetectable estrogen
    • Amenorrhea or oligomenorrhea lasting over 4 months
    • Low Anti-Müllerian Hormone (AMH) levels
  • No ongoing hormone replacement therapy (HRT) or able to temporarily discontinue it
  • At least one ovary intact and visible on transvaginal ultrasound
  • No severe structural abnormalities of the uterus or ovaries
  • Willingness to undergo follow-up monitoring (blood tests and ultrasounds for at least 6–12 months)

EXCLUSION Criteria

You may NOT be eligible if you meet any of the following conditions:

  • Age over 43 with confirmed total follicular depletion (ovarian atrophy or fibrosis)
  • Active autoimmune disease attacking ovarian tissue (e.g. lupus, Hashimoto’s thyroiditis without control)
  • History of ovarian or reproductive tract cancer
  • Current pregnancy or breastfeeding
  • Severe coagulation disorders or active infections
  • Pelvic anatomical abnormalities that prevent safe transvaginal access
  • Use of cytotoxic medications (e.g. chemotherapy) within the last 6 months
  • Psychological or psychiatric conditions interfering with compliance or consent

Pre-Treatment Testing Checklist

To determine eligibility, patients typically undergo:

  • Hormone panel: FSH, LH, E2, AMH
  • Pelvic ultrasound (antral follicle count and ovarian volume)
  • Infectious disease screening
  • Basic blood work (CBC, CRP, coagulation profile)
  • Medical history review and physician consultation

Learn how Stem Cells and Exosomes can change your life!

When?

Today! Reach out to us with confidence and discover the world’s most innovative solutions for Premature Ovarian Failure. Our experts are here for you — ready to provide all the information and support you need to feel like yourself again.

Where?

Help Desk +390549909905
Help Desk info@bioinst.com

Como (Italy)
Milano (Italy)
Rome (Italy)
Varese (Italy)
Falciano (RSM)

Stromal Vascular Fraction (SVF) VS Mesenchymal Stem Cells (MSC)

In the regenerative medicine landscape, many providers offer therapies labeled as "Stem Cell treatments" that utilize Stromal Vascular Fraction (SVF)—a heterogeneous mix of cells extracted from adipose tissue. While SVF contains some Stem Cells, it also includes various other cell types, leading to variability in treatment outcomes.
At our Clinic, we prioritize precision and efficacy by exclusively using Mesenchymal Stem Cells (MSCs). These are meticulously isolated and expanded in controlled laboratory settings, ensuring a pure, potent, and standardized cell population. This approach enhances the therapeutic potential and consistency of our treatments.

Standard Product and Therapy

MSC
YES, A pharma-grade product derived from a cell isolation and culture process, subject to strict quality control procedures

SVF
NO, Composition varies based on the collection site, the patient’s biological age, the digestion technique used, and several other factors.

Cellular Homogeneity

MSC
YES, Isolated and phenotyped cells

SVF
NO, Heterogeneous cell population

Concentration of MSC

MSC
100%

SVF
Between 0,001% and 0,01% of the total cells within

MSC per 10ml FAT

MSC
>100.000.000 after expansion

SVF
Around 9.000

Microphages per 10ml FAT

MSC
0 - Eliminated through isolation of MSCs

SVF
>400.000

Side Effects

MSC
NO

SVF
YES, often unpredictable, usually mediated by inflammatory processes caused by the macrophage population or potential bacterial contamination

Dosage

MSC
VARIOUS DOSAGES AVAILABLE
10-200 millions of MSC (based on indications)

SVF
SINGLE DOSAGE
not tailored to treatment

Safety

MSC
Pharma-grade production process, subjected to quality controls that ensure product sterility and biological safety

SVF
The production process is not monitorable and not subject to quality and biological safety controls

Treatments from 1 fat Collection

MSC
≥10

SVF
1

Phenotyping

MSC
YES

SVF
NO

Cellular Composition

MSC
Mesenchymal Stem Cells

SVF
Pericytes, Macrophages, Endothelial Cells, Mesenchymal Stem Cells, Adipocytes, Lymphocytes, Fibroblasts

Quality Control

MSC
Endotoxins, Mycoplasma, Anaerobic/Aerobic Bacteria, Viruses, Phenotype

SVF
None

Production Time

MSC
2-4 Weeks

SVF
1 hour

FDA Approval

MSC
YES (Ryoncil 18-12-2024)

SVF
NO

EMA Approval

MSC
YES (Alofisel, Spherox, Ryoncil)

SVF
NO

Usage

MSC
Autologous and Allogenic Localized and Systemic

SVF
Strictly Autologous, Homologous, and Localized

    POWERED BY

    BioScience Institute

    As the world’s leading center of Stem Cell and Regenerative Medicine, Bioscience offers unparalleled service and treatments, unique only to it. Bioscience offers the most advanced personalized expanded adipose derived Stem Cell therapies across Europe – including Rome, Milan, and San Marino, and the Middle East, including Dubai.

    The team at Bioscience Institute does not believe in using invasive surgeries when they can be partially replaced by cell biology. Therefore, they have designed an alternative method of extracting stem cells from adipose tissue. As a distinctive and versatile offering, adipose tissue provides an effective solution to all of Bioscience regenerative services, ranging from to hair loss treatments, to skin aging, to body reshaping treatments.

    Bioscience Institute Vision

    The beauty of regenerative medicine therapies and Stem Cell treatments comes from the ability to use your own body to help heal and enhance your well-being through living body tissue. Bioscience Institute’s vision is based on using this most effective and advanced Stem Cell treatments that is based on cell biology and Exosomes to help amplify our natural healing process in the areas it is needed most or take over the function of damaged tissue altogether.

    Stem cells verified treatments

    With the ability to develop methods to regrow, repair, or replace damaged cells and tissues, using Stem Cell & regenerative medicines provides a natural method of treatment that is less traumatic to the body and more effective than other more invasive treatments and surgeries. The stem cell therapies provided by Bioscience Institute are verified in Europe and the Middle East by scientific evidence of increased safety and efficiency than any other treatment method.

    Scientific Research

    The Bioscience’s profits are consistently reinvested into developing research. Avoiding a flashy commercial profile allows us to concentrate on using investments to create better treatments and ultimately help clients globally. Due to this commitment, Bioscience Institute has instigated important scientific collaborations with leading universities, pioneering procedures and methods around cell products.

    Bioscience Cell Factory and Clinic in Dubai, San Marino, Italy & Switzerland

    Bioscience Institute is the first and only GMP-certified Clinic in the Middle East and Europe, offering stem cell treatments with the most advanced personalized autologous cell therapies worldwide.
    Offering a unique service and treatment sets it apart from any form of competition and allows it to give clients the care, attention, and treatment they deserve.

    • Bioscience Clinics in the Middle East and Europe include a fully equipped facility needed to carry out any treatments offered, whether Stem Cell treatments or banking.
    • Bioscience Laboratory is a dedicated Cell Banking Factory used to store and expand Adipose-Derived Cells and Fibroblasts to help ensure that the clients’ needs can always and easily be catered to.